Lilly Rides To Solid First Quarter On Diabetes, Newer Products
Smarting from a disappointing advisory committee review for baricitinib, Lilly pointed to the strong first quarter performance of its drugs launched since 2014, especially Trulicity.
Smarting from a disappointing advisory committee review for baricitinib, Lilly pointed to the strong first quarter performance of its drugs launched since 2014, especially Trulicity.